Thus, recent findings targeting GITR, a surface immunomodulatory receptor highly expressed on GBM Tregs but lowly expressed on systemic Tregs, are especially encouraging for Treg depletion therapies. This evidence concerns the gene TNFRSF18 and glioblastoma.